APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pulmonary Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Pulmonary Drugs Industry Growth and Trends Forecast to 2032

22 December 2025124 pages

Choose your research edition.

Industry ResearchPulmonary Drugs Industry Research Report 2026141 pages · $2,950 USDIndustry Growth & TrendsGlobal Pulmonary Drugs Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Pulmonary Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pulmonary Drugs Market Outlook and Growth Opportunities 2026211 pages · $4,250 USDMarket Analysis & ForecastGlobal Pulmonary Drugs Market Analysis and Forecast 2026-2032219 pages · $4,950 USD

Market perspective

According to APO Research, the global Pulmonary Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Pulmonary Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Pulmonary Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pulmonary Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Pulmonary Drugs market include Teva Pharmaceutical Industries Ltd., Sanofi SA, Novartis AG, GlaxoSmithKline Plc., Glenmark Pharmaceuticals Ltd., AbbVie Inc., AstraZeneca Plc., Zambon Company S.p.A and Wellona Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Pulmonary Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Pulmonary Drugs market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Pulmonary Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Pulmonary Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Pulmonary Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Pulmonary Drugs Market by Company

Teva Pharmaceutical Industries Ltd.

Sanofi SA

Novartis AG

GlaxoSmithKline Plc.

Glenmark Pharmaceuticals Ltd.

AbbVie Inc.

AstraZeneca Plc.

Zambon Company S.p.A

Wellona Pharma

Vertex Pharmaceuticals Inc.

Sumitomo Pharma Co. Ltd.

Merck Sharp & Dohme Limited

Medisol Lifescience Pvt. Ltd.

Meda Pharmaceuticals

Mallinckrodt Pharmaceuticals Plc.

Lupin Ltd.

Grifols, S.A.

F. Hoffmann La Roche Ltd.

Circassia Pharmaceuticals Plc.

Cipla Ltd.

Cheisi Farmaceutici S.p.A

Celon Pharma SA

Boehringer Ingelheim

Aurobindo Pharma Ltd.

Alaxia SAS

Aerogen Pharma Ltd.

Abbott Laboratories

Pulmonary Drugs Segment by Type

Antihistamines

Inhaled Corticosteroids

Vasodilators

Long Acting Beta-2 Agonists

Others

Pulmonary Drugs Segment by Application

Asthma & COPD

Cystic Fibrosis

Pulmonary Arterial Hypertension

Allergic Rhinitis

Others

Pulmonary Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmonary Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pulmonary Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmonary Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Pulmonary Drugs companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Pulmonary Drugs Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Pulmonary Drugs Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Pulmonary Drugs Market Share by Region (2021-2026) Table 4. Global Pulmonary Drugs Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Pulmonary Drugs Market Share by Region (2027-2032) Table 6. Global Pulmonary Drugs Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Pulmonary Drugs Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Pulmonary Drugs Market Size Share by Type (2021-2026) Table 9. Global Pulmonary Drugs Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Pulmonary Drugs Market Size Share Forecasted by Type (2027-2032) Table 11. North America Pulmonary Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Pulmonary Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Pulmonary Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Pulmonary Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Pulmonary Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Pulmonary Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Pulmonary Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Pulmonary Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Pulmonary Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Pulmonary Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Pulmonary Drugs Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Pulmonary Drugs Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Pulmonary Drugs Market Size Share by Application (2021-2026) Table 24. Global Pulmonary Drugs Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Pulmonary Drugs Market Size Share Forecasted by Application (2027-2032) Table 26. North America Pulmonary Drugs Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Pulmonary Drugs Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Pulmonary Drugs Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Pulmonary Drugs Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Pulmonary Drugs Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Pulmonary Drugs Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Pulmonary Drugs Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Pulmonary Drugs Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Pulmonary Drugs Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Pulmonary Drugs Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Pulmonary Drugs Industry Trends Table 37. Pulmonary Drugs Industry Drivers Table 38. Pulmonary Drugs Industry Opportunities and Challenges Table 39. Pulmonary Drugs Industry Restraints Table 40. Global Pulmonary Drugs Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Pulmonary Drugs Revenue Market Share by Company (2021-2026) Table 42. Global Pulmonary Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Pulmonary Drugs Key Company Headquarters & Area Served Table 44. Global Pulmonary Drugs Company, Product Type & Application Table 45. Global Pulmonary Drugs Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Pulmonary Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Teva Pharmaceutical Industries Ltd. Company Information Table 49. Teva Pharmaceutical Industries Ltd. Business Overview Table 50. Teva Pharmaceutical Industries Ltd. Pulmonary Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Teva Pharmaceutical Industries Ltd. Pulmonary Drugs Product Portfolio Table 52. Teva Pharmaceutical Industries Ltd. Recent Development Table 53. Sanofi SA Company Information Table 54. Sanofi SA Business Overview Table 55. Sanofi SA Pulmonary Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Sanofi SA Pulmonary Drugs Product Portfolio Table 57. Sanofi SA Recent Development Table 58. Novartis AG Company Information Table 59. Novartis AG Business Overview Table 60. Novartis AG Pulmonary Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Novartis AG Pulmonary Drugs Product Portfolio Table 62. Novartis AG Recent Development Table 63. GlaxoSmithKline Plc. Company Information Table 64. GlaxoSmithKline Plc. Business Overview Table 65. GlaxoSmithKline Plc. Pulmonary Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. GlaxoSmithKline Plc. Pulmonary Drugs Product Portfolio Table 67. GlaxoSmithKline Plc. Recent Development Table 68. Glenmark Pharmaceuticals Ltd. Company Information Table 69. Glenmark Pharmaceuticals Ltd. Business Overview Table 70. Glenmark Pharmaceuticals Ltd. Pulmonary Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Glenmark Pharmaceuticals Ltd. Pulmonary Drugs Product Portfolio Table 72. Glenmark Pharmaceuticals Ltd. Recent Development Table 73. AbbVie Inc. Company Information Table 74. AbbVie Inc. Business Overview Table 75. AbbVie Inc. Pulmonary Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. AbbVie Inc. Pulmonary Drugs Product Portfolio Table 77. AbbVie Inc. Recent Development Table 78. AstraZeneca Plc. Company Information Table 79. AstraZeneca Plc. Business Overview Table 80. AstraZeneca Plc. Pulmonary Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. AstraZeneca Plc. Pulmonary Drugs Product Portfolio Table 82. AstraZeneca Plc. Recent Development Table 83. Zambon Company S.p.A Company Information Table 84. Zambon Company S.p.A Business Overview Table 85. Zambon Company S.p.A Pulmonary Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Zambon Company S.p.A Pulmonary Drugs Product Portfolio Table 87. Zambon Company S.p.A Recent Development Table 88. Wellona Pharma Company Information Table 89. Wellona Pharma Business Overview Table 90. Wellona Pharma Pulmonary Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Wellona Pharma Pulmonary Drugs Product Portfolio Table 92. Wellona Pharma Recent Development Table 93. Vertex Pharmaceuticals Inc. Company Information Table 94. Vertex Pharmaceuticals Inc. Business Overview Table 95. Vertex Pharmaceuticals Inc. Pulmonary Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Vertex Pharmaceuticals Inc. Pulmonary Drugs Product Portfolio Table 97. Vertex Pharmaceuticals Inc. Recent Development Table 98. Sumitomo Pharma Co. Ltd. Company Information Table 99. Sumitomo Pharma Co. Ltd. Business Overview Table 100. Sumitomo Pharma Co. Ltd. Pulmonary Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Sumitomo Pharma Co. Ltd. Pulmonary Drugs Product Portfolio Table 102. Sumitomo Pharma Co. Ltd. Recent Development Table 103. Merck Sharp & Dohme Limited Company Information Table 104. Merck Sharp & Dohme Limited Business Overview Table 105. Merck Sharp & Dohme Limited Pulmonary Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Merck Sharp & Dohme Limited Pulmonary Drugs Product Portfolio Table 107. Merck Sharp & Dohme Limited Recent Development Table 108. Medisol Lifescience Pvt. Ltd. Company Information Table 109. Medisol Lifescience Pvt. Ltd. Business Overview Table 110. Medisol Lifescience Pvt. Ltd. Pulmonary Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. Medisol Lifescience Pvt. Ltd. Pulmonary Drugs Product Portfolio Table 112. Medisol Lifescience Pvt. Ltd. Recent Development Table 113. Meda Pharmaceuticals Company Information Table 114. Meda Pharmaceuticals Business Overview Table 115. Meda Pharmaceuticals Pulmonary Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. Meda Pharmaceuticals Pulmonary Drugs Product Portfolio Table 117. Meda Pharmaceuticals Recent Development Table 118. Mallinckrodt Pharmaceuticals Plc. Company Information Table 119. Mallinckrodt Pharmaceuticals Plc. Business Overview Table 120. Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Product Portfolio Table 122. Mallinckrodt Pharmaceuticals Plc. Recent Development Table 123. Lupin Ltd. Company Information Table 124. Lupin Ltd. Business Overview Table 125. Lupin Ltd. Pulmonary Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. Lupin Ltd. Pulmonary Drugs Product Portfolio Table 127. Lupin Ltd. Recent Development Table 128. Grifols, S.A. Company Information Table 129. Grifols, S.A. Business Overview Table 130. Grifols, S.A. Pulmonary Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 131. Grifols, S.A. Pulmonary Drugs Product Portfolio Table 132. Grifols, S.A. Recent Development Table 133. F. Hoffmann La Roche Ltd. Company Information Table 134. F. Hoffmann La Roche Ltd. Business Overview Table 135. F. Hoffmann La Roche Ltd. Pulmonary Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 136. F. Hoffmann La Roche Ltd. Pulmonary Drugs Product Portfolio Table 137. F. Hoffmann La Roche Ltd. Recent Development Table 138. Circassia Pharmaceuticals Plc. Company Information Table 139. Circassia Pharmaceuticals Plc. Business Overview Table 140. Circassia Pharmaceuticals Plc. Pulmonary Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 141. Circassia Pharmaceuticals Plc. Pulmonary Drugs Product Portfolio Table 142. Circassia Pharmaceuticals Plc. Recent Development Table 143. Cipla Ltd. Company Information Table 144. Cipla Ltd. Business Overview Table 145. Cipla Ltd. Pulmonary Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 146. Cipla Ltd. Pulmonary Drugs Product Portfolio Table 147. Cipla Ltd. Recent Development Table 148. Cheisi Farmaceutici S.p.A Company Information Table 149. Cheisi Farmaceutici S.p.A Business Overview Table 150. Cheisi Farmaceutici S.p.A Pulmonary Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 151. Cheisi Farmaceutici S.p.A Pulmonary Drugs Product Portfolio Table 152. Cheisi Farmaceutici S.p.A Recent Development Table 153. Celon Pharma SA Company Information Table 154. Celon Pharma SA Business Overview Table 155. Celon Pharma SA Pulmonary Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 156. Celon Pharma SA Pulmonary Drugs Product Portfolio Table 157. Celon Pharma SA Recent Development Table 158. Boehringer Ingelheim Company Information Table 159. Boehringer Ingelheim Business Overview Table 160. Boehringer Ingelheim Pulmonary Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 161. Boehringer Ingelheim Pulmonary Drugs Product Portfolio Table 162. Boehringer Ingelheim Recent Development Table 163. Aurobindo Pharma Ltd. Company Information Table 164. Aurobindo Pharma Ltd. Business Overview Table 165. Aurobindo Pharma Ltd. Pulmonary Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 166. Aurobindo Pharma Ltd. Pulmonary Drugs Product Portfolio Table 167. Aurobindo Pharma Ltd. Recent Development Table 168. Alaxia SAS Company Information Table 169. Alaxia SAS Business Overview Table 170. Alaxia SAS Pulmonary Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 171. Alaxia SAS Pulmonary Drugs Product Portfolio Table 172. Alaxia SAS Recent Development Table 173. Aerogen Pharma Ltd. Company Information Table 174. Aerogen Pharma Ltd. Business Overview Table 175. Aerogen Pharma Ltd. Pulmonary Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 176. Aerogen Pharma Ltd. Pulmonary Drugs Product Portfolio Table 177. Aerogen Pharma Ltd. Recent Development Table 178. Abbott Laboratories Company Information Table 179. Abbott Laboratories Business Overview Table 180. Abbott Laboratories Pulmonary Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 181. Abbott Laboratories Pulmonary Drugs Product Portfolio Table 182. Abbott Laboratories Recent Development Table 183. North America Pulmonary Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 184. North America Pulmonary Drugs Market Size by Country (2021-2026) & (US$ Million) Table 185. North America Pulmonary Drugs Market Share by Country (2021-2026) Table 186. North America Pulmonary Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 187. North America Pulmonary Drugs Market Share Forecast by Country (2027-2032) Table 188. Europe Pulmonary Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 189. Europe Pulmonary Drugs Market Size by Country (2021-2026) & (US$ Million) Table 190. Europe Pulmonary Drugs Market Share by Country (2021-2026) Table 191. Europe Pulmonary Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 192. Europe Pulmonary Drugs Market Share Forecast by Country (2027-2032) Table 193. Asia-Pacific Pulmonary Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 194. Asia-Pacific Pulmonary Drugs Market Size by Country (2021-2026) & (US$ Million) Table 195. Asia-Pacific Pulmonary Drugs Market Share by Country (2021-2026) Table 196. Asia-Pacific Pulmonary Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 197. Asia-Pacific Pulmonary Drugs Market Share Forecast by Country (2027-2032) Table 198. Latin America Pulmonary Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 199. Latin America Pulmonary Drugs Market Size by Country (2021-2026) & (US$ Million) Table 200. Latin America Pulmonary Drugs Market Share by Country (2021-2026) Table 201. Latin America Pulmonary Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 202. Latin America Pulmonary Drugs Market Share Forecast by Country (2027-2032) Table 203. Middle East & Africa Pulmonary Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 204. Middle East & Africa Pulmonary Drugs Market Size by Country (2021-2026) & (US$ Million) Table 205. Middle East & Africa Pulmonary Drugs Market Share by Country (2021-2026) Table 206. Middle East & Africa Pulmonary Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 207. Middle East & Africa Pulmonary Drugs Market Share Forecast by Country (2027-2032) Table 208. Research Programs/Design for This Report Table 209. Authors List of This Report Table 210. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Pulmonary Drugs Product Image Figure 3. Global Pulmonary Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Pulmonary Drugs Market Size (2021-2032) & (US$ Million) Figure 5. Global Pulmonary Drugs Market Share by Region: 2025 VS 2032 Figure 6. Global Pulmonary Drugs Market Share by Region (2021-2032) Figure 7. North America Pulmonary Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Pulmonary Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Pulmonary Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Pulmonary Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Pulmonary Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Antihistamines Image Figure 13. Global Antihistamines Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Inhaled Corticosteroids Image Figure 15. Global Inhaled Corticosteroids Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Vasodilators Image Figure 17. Global Vasodilators Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Long Acting Beta-2 Agonists Image Figure 19. Global Long Acting Beta-2 Agonists Market Size YoY Growth (2021-2032) & (US$ Million) Figure 20. Others Image Figure 21. Global Others Market Size YoY Growth (2021-2032) & (US$ Million) Figure 22. Global Pulmonary Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 23. Global Pulmonary Drugs Market Share by Type 2025 VS 2032 Figure 24. North America Pulmonary Drugs Market Size Share by Type (2021-2032) Figure 25. Europe Pulmonary Drugs Market Size Share by Type (2021-2032) Figure 26. Asia-Pacific Pulmonary Drugs Market Size Share by Type (2021-2032) Figure 27. Latin America Pulmonary Drugs Market Size Share by Type (2021-2032) Figure 28. Middle East and Africa Pulmonary Drugs Market Size Share by Type (2021-2032) Figure 29. Asthma & COPD Image Figure 30. Global Asthma & COPD Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Cystic Fibrosis Image Figure 32. Global Cystic Fibrosis Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Pulmonary Arterial Hypertension Image Figure 34. Global Pulmonary Arterial Hypertension Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Allergic Rhinitis Image Figure 36. Global Allergic Rhinitis Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Others Image Figure 38. Global Others Market Size YoY Growth (2021-2032) & (US$ Million) Figure 39. Global Pulmonary Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 40. Global Pulmonary Drugs Market Share by Application 2025 VS 2032 Figure 41. North America Pulmonary Drugs Market Size Share by Application (2021-2032) Figure 42. Europe Pulmonary Drugs Market Size Share by Application (2021-2032) Figure 43. Asia-Pacific Pulmonary Drugs Market Size Share by Application (2021-2032) Figure 44. Latin America Pulmonary Drugs Market Size Share by Application (2021-2032) Figure 45. Middle East and Africa Pulmonary Drugs Market Size Share by Application (2021-2032) Figure 46. Global Top 5 and 10 Pulmonary Drugs Players Market Share by Revenue in 2025 Figure 47. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 48. North America Pulmonary Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 49. North America Pulmonary Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 50. North America Pulmonary Drugs Market Share by Country (2021-2032) Figure 51. Europe Pulmonary Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Pulmonary Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Pulmonary Drugs Market Share by Country (2021-2032) Figure 54. Asia-Pacific Pulmonary Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Asia-Pacific Pulmonary Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 56. Asia-Pacific Pulmonary Drugs Market Share by Country (2021-2032) Figure 57. Latin America Pulmonary Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Pulmonary Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Pulmonary Drugs Market Share by Country (2021-2032) Figure 60. Middle East & Africa Pulmonary Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Middle East & Africa Pulmonary Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 62. Middle East & Africa Pulmonary Drugs Market Share by Country (2021-2032) Figure 63. Years Considered Figure 64. Research Process Figure 65. Key Executives Interviewed

Scope & coverage.

Types
  • Antihistamines
  • Inhaled Corticosteroids
  • Vasodilators
  • Long Acting Beta-2 Agonists
  • Others
Applications
  • Asthma & COPD
  • Cystic Fibrosis
  • Pulmonary Arterial Hypertension
  • Allergic Rhinitis
  • Others
Companies covered
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi SA
  • Novartis AG
  • GlaxoSmithKline Plc.
  • Glenmark Pharmaceuticals Ltd.
  • AbbVie Inc.
  • AstraZeneca Plc.
  • Zambon Company S.p.A
  • Wellona Pharma
  • Vertex Pharmaceuticals Inc.
  • Sumitomo Pharma Co. Ltd.
  • Merck Sharp & Dohme Limited
  • Medisol Lifescience Pvt. Ltd.
  • Meda Pharmaceuticals
  • Mallinckrodt Pharmaceuticals Plc.
  • Lupin Ltd.
  • Grifols, S.A.
  • F. Hoffmann La Roche Ltd.
  • Circassia Pharmaceuticals Plc.
  • Cipla Ltd.
  • Cheisi Farmaceutici S.p.A
  • Celon Pharma SA
  • Boehringer Ingelheim
  • Aurobindo Pharma Ltd.
  • Alaxia SAS
  • Aerogen Pharma Ltd.
  • Abbott Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Pulmonary Drugs Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Pulmonary Drugs Market Size by Region (2021-2032)
  5. 1.4.1 Global Pulmonary Drugs Market Size by Region (2021-2026)
  6. 1.4.2 Global Pulmonary Drugs Market Size by Region (2027-2032)
  7. 1.5 Key Regions Pulmonary Drugs Market Size (2021-2032)
  8. 1.5.1 North America Pulmonary Drugs Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Pulmonary Drugs Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Pulmonary Drugs Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Pulmonary Drugs Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Pulmonary Drugs Market Size Growth Rate (2021-2032)
2 Pulmonary Drugs Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Antihistamines
  3. 2.1.2 Inhaled Corticosteroids
  4. 2.1.3 Vasodilators
  5. 2.1.4 Long Acting Beta-2 Agonists
  6. 2.1.5 Others
  7. 2.2 Global Pulmonary Drugs Market Size by Type
  8. 2.2.1 Global Pulmonary Drugs Market Size Overview by Type (2021-2032)
  9. 2.2.2 Global Pulmonary Drugs Historic Market Size Review by Type (2021-2026)
  10. 2.2.3 Global Pulmonary Drugs Market Size Forecasted by Type (2027-2032)
  11. 2.3 Global Pulmonary Drugs Market Size by Regions
  12. 2.3.1 North America Pulmonary Drugs Market Size Breakdown by Type (2021-2026)
  13. 2.3.2 Europe Pulmonary Drugs Market Size Breakdown by Type (2021-2026)
  14. 2.3.3 Asia-Pacific Pulmonary Drugs Market Size Breakdown by Type (2021-2026)
  15. 2.3.4 South America Pulmonary Drugs Market Size Breakdown by Type (2021-2026)
  16. 2.3.5 Middle East and Africa Pulmonary Drugs Market Size Breakdown by Type (2021-2026)
3 Pulmonary Drugs Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Asthma & COPD
  3. 3.1.2 Cystic Fibrosis
  4. 3.1.3 Pulmonary Arterial Hypertension
  5. 3.1.4 Allergic Rhinitis
  6. 3.1.5 Others
  7. 3.2 Global Pulmonary Drugs Market Size by Application
  8. 3.2.1 Global Pulmonary Drugs Market Size Overview by Application (2021-2032)
  9. 3.2.2 Global Pulmonary Drugs Historic Market Size Review by Application (2021-2026)
  10. 3.2.3 Global Pulmonary Drugs Market Size Forecasted by Application (2027-2032)
  11. 3.3 Global Pulmonary Drugs Market Size by Regions
  12. 3.3.1 North America Pulmonary Drugs Market Size Breakdown by Application (2021-2026)
  13. 3.3.2 Europe Pulmonary Drugs Market Size Breakdown by Application (2021-2026)
  14. 3.3.3 Asia-Pacific Pulmonary Drugs Market Size Breakdown by Application (2021-2026)
  15. 3.3.4 South America Pulmonary Drugs Market Size Breakdown by Application (2021-2026)
  16. 3.3.5 Middle East and Africa Pulmonary Drugs Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Pulmonary Drugs Industry Trends
  2. 4.2 Pulmonary Drugs Industry Drivers
  3. 4.3 Pulmonary Drugs Industry Opportunities and Challenges
  4. 4.4 Pulmonary Drugs Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Pulmonary Drugs Revenue (2021-2026)
  2. 5.2 Global Pulmonary Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Pulmonary Drugs Key Company Headquarters & Area Served
  4. 5.4 Global Pulmonary Drugs Company, Product Type & Application
  5. 5.5 Global Pulmonary Drugs Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Pulmonary Drugs Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Pulmonary Drugs Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Pulmonary Drugs Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Teva Pharmaceutical Industries Ltd.
  2. 6.1.1 Teva Pharmaceutical Industries Ltd. Company Information
  3. 6.1.2 Teva Pharmaceutical Industries Ltd. Business Overview
  4. 6.1.3 Teva Pharmaceutical Industries Ltd. Pulmonary Drugs Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Teva Pharmaceutical Industries Ltd. Pulmonary Drugs Product Portfolio
  6. 6.1.5 Teva Pharmaceutical Industries Ltd. Recent Developments
  7. 6.2 Sanofi SA
  8. 6.2.1 Sanofi SA Company Information
  9. 6.2.2 Sanofi SA Business Overview
  10. 6.2.3 Sanofi SA Pulmonary Drugs Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Sanofi SA Pulmonary Drugs Product Portfolio
  12. 6.2.5 Sanofi SA Recent Developments
  13. 6.3 Novartis AG
  14. 6.3.1 Novartis AG Company Information
  15. 6.3.2 Novartis AG Business Overview
  16. 6.3.3 Novartis AG Pulmonary Drugs Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Novartis AG Pulmonary Drugs Product Portfolio
  18. 6.3.5 Novartis AG Recent Developments
  19. 6.4 GlaxoSmithKline Plc.
  20. 6.4.1 GlaxoSmithKline Plc. Company Information
  21. 6.4.2 GlaxoSmithKline Plc. Business Overview
  22. 6.4.3 GlaxoSmithKline Plc. Pulmonary Drugs Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 GlaxoSmithKline Plc. Pulmonary Drugs Product Portfolio
  24. 6.4.5 GlaxoSmithKline Plc. Recent Developments
  25. 6.5 Glenmark Pharmaceuticals Ltd.
  26. 6.5.1 Glenmark Pharmaceuticals Ltd. Company Information
  27. 6.5.2 Glenmark Pharmaceuticals Ltd. Business Overview
  28. 6.5.3 Glenmark Pharmaceuticals Ltd. Pulmonary Drugs Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Glenmark Pharmaceuticals Ltd. Pulmonary Drugs Product Portfolio
  30. 6.5.5 Glenmark Pharmaceuticals Ltd. Recent Developments
  31. 6.6 AbbVie Inc.
  32. 6.6.1 AbbVie Inc. Company Information
  33. 6.6.2 AbbVie Inc. Business Overview
  34. 6.6.3 AbbVie Inc. Pulmonary Drugs Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 AbbVie Inc. Pulmonary Drugs Product Portfolio
  36. 6.6.5 AbbVie Inc. Recent Developments
  37. 6.7 AstraZeneca Plc.
  38. 6.7.1 AstraZeneca Plc. Company Information
  39. 6.7.2 AstraZeneca Plc. Business Overview
  40. 6.7.3 AstraZeneca Plc. Pulmonary Drugs Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 AstraZeneca Plc. Pulmonary Drugs Product Portfolio
  42. 6.7.5 AstraZeneca Plc. Recent Developments
  43. 6.8 Zambon Company S.p.A
  44. 6.8.1 Zambon Company S.p.A Company Information
  45. 6.8.2 Zambon Company S.p.A Business Overview
  46. 6.8.3 Zambon Company S.p.A Pulmonary Drugs Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Zambon Company S.p.A Pulmonary Drugs Product Portfolio
  48. 6.8.5 Zambon Company S.p.A Recent Developments
  49. 6.9 Wellona Pharma
  50. 6.9.1 Wellona Pharma Company Information
  51. 6.9.2 Wellona Pharma Business Overview
  52. 6.9.3 Wellona Pharma Pulmonary Drugs Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Wellona Pharma Pulmonary Drugs Product Portfolio
  54. 6.9.5 Wellona Pharma Recent Developments
  55. 6.10 Vertex Pharmaceuticals Inc.
  56. 6.10.1 Vertex Pharmaceuticals Inc. Company Information
  57. 6.10.2 Vertex Pharmaceuticals Inc. Business Overview
  58. 6.10.3 Vertex Pharmaceuticals Inc. Pulmonary Drugs Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Vertex Pharmaceuticals Inc. Pulmonary Drugs Product Portfolio
  60. 6.10.5 Vertex Pharmaceuticals Inc. Recent Developments
  61. 6.11 Sumitomo Pharma Co. Ltd.
  62. 6.11.1 Sumitomo Pharma Co. Ltd. Company Information
  63. 6.11.2 Sumitomo Pharma Co. Ltd. Business Overview
  64. 6.11.3 Sumitomo Pharma Co. Ltd. Pulmonary Drugs Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Sumitomo Pharma Co. Ltd. Pulmonary Drugs Product Portfolio
  66. 6.11.5 Sumitomo Pharma Co. Ltd. Recent Developments
  67. 6.12 Merck Sharp & Dohme Limited
  68. 6.12.1 Merck Sharp & Dohme Limited Company Information
  69. 6.12.2 Merck Sharp & Dohme Limited Business Overview
  70. 6.12.3 Merck Sharp & Dohme Limited Pulmonary Drugs Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Merck Sharp & Dohme Limited Pulmonary Drugs Product Portfolio
  72. 6.12.5 Merck Sharp & Dohme Limited Recent Developments
  73. 6.13 Medisol Lifescience Pvt. Ltd.
  74. 6.13.1 Medisol Lifescience Pvt. Ltd. Company Information
  75. 6.13.2 Medisol Lifescience Pvt. Ltd. Business Overview
  76. 6.13.3 Medisol Lifescience Pvt. Ltd. Pulmonary Drugs Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 Medisol Lifescience Pvt. Ltd. Pulmonary Drugs Product Portfolio
  78. 6.13.5 Medisol Lifescience Pvt. Ltd. Recent Developments
  79. 6.14 Meda Pharmaceuticals
  80. 6.14.1 Meda Pharmaceuticals Company Information
  81. 6.14.2 Meda Pharmaceuticals Business Overview
  82. 6.14.3 Meda Pharmaceuticals Pulmonary Drugs Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 Meda Pharmaceuticals Pulmonary Drugs Product Portfolio
  84. 6.14.5 Meda Pharmaceuticals Recent Developments
  85. 6.15 Mallinckrodt Pharmaceuticals Plc.
  86. 6.15.1 Mallinckrodt Pharmaceuticals Plc. Company Information
  87. 6.15.2 Mallinckrodt Pharmaceuticals Plc. Business Overview
  88. 6.15.3 Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Product Portfolio
  90. 6.15.5 Mallinckrodt Pharmaceuticals Plc. Recent Developments
  91. 6.16 Lupin Ltd.
  92. 6.16.1 Lupin Ltd. Company Information
  93. 6.16.2 Lupin Ltd. Business Overview
  94. 6.16.3 Lupin Ltd. Pulmonary Drugs Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 Lupin Ltd. Pulmonary Drugs Product Portfolio
  96. 6.16.5 Lupin Ltd. Recent Developments
  97. 6.17 Grifols, S.A.
  98. 6.17.1 Grifols, S.A. Company Information
  99. 6.17.2 Grifols, S.A. Business Overview
  100. 6.17.3 Grifols, S.A. Pulmonary Drugs Revenue, Global Share and Gross Margin (2021-2026)
  101. 6.17.4 Grifols, S.A. Pulmonary Drugs Product Portfolio
  102. 6.17.5 Grifols, S.A. Recent Developments
  103. 6.18 F. Hoffmann La Roche Ltd.
  104. 6.18.1 F. Hoffmann La Roche Ltd. Company Information
  105. 6.18.2 F. Hoffmann La Roche Ltd. Business Overview
  106. 6.18.3 F. Hoffmann La Roche Ltd. Pulmonary Drugs Revenue, Global Share and Gross Margin (2021-2026)
  107. 6.18.4 F. Hoffmann La Roche Ltd. Pulmonary Drugs Product Portfolio
  108. 6.18.5 F. Hoffmann La Roche Ltd. Recent Developments
  109. 6.19 Circassia Pharmaceuticals Plc.
  110. 6.19.1 Circassia Pharmaceuticals Plc. Company Information
  111. 6.19.2 Circassia Pharmaceuticals Plc. Business Overview
  112. 6.19.3 Circassia Pharmaceuticals Plc. Pulmonary Drugs Revenue, Global Share and Gross Margin (2021-2026)
  113. 6.19.4 Circassia Pharmaceuticals Plc. Pulmonary Drugs Product Portfolio
  114. 6.19.5 Circassia Pharmaceuticals Plc. Recent Developments
  115. 6.20 Cipla Ltd.
  116. 6.20.1 Cipla Ltd. Company Information
  117. 6.20.2 Cipla Ltd. Business Overview
  118. 6.20.3 Cipla Ltd. Pulmonary Drugs Revenue, Global Share and Gross Margin (2021-2026)
  119. 6.20.4 Cipla Ltd. Pulmonary Drugs Product Portfolio
  120. 6.20.5 Cipla Ltd. Recent Developments
  121. 6.21 Cheisi Farmaceutici S.p.A
  122. 6.21.1 Cheisi Farmaceutici S.p.A Company Information
  123. 6.21.2 Cheisi Farmaceutici S.p.A Business Overview
  124. 6.21.3 Cheisi Farmaceutici S.p.A Pulmonary Drugs Revenue, Global Share and Gross Margin (2021-2026)
  125. 6.21.4 Cheisi Farmaceutici S.p.A Pulmonary Drugs Product Portfolio
  126. 6.21.5 Cheisi Farmaceutici S.p.A Recent Developments
  127. 6.22 Celon Pharma SA
  128. 6.22.1 Celon Pharma SA Company Information
  129. 6.22.2 Celon Pharma SA Business Overview
  130. 6.22.3 Celon Pharma SA Pulmonary Drugs Revenue, Global Share and Gross Margin (2021-2026)
  131. 6.22.4 Celon Pharma SA Pulmonary Drugs Product Portfolio
  132. 6.22.5 Celon Pharma SA Recent Developments
  133. 6.23 Boehringer Ingelheim
  134. 6.23.1 Boehringer Ingelheim Company Information
  135. 6.23.2 Boehringer Ingelheim Business Overview
  136. 6.23.3 Boehringer Ingelheim Pulmonary Drugs Revenue, Global Share and Gross Margin (2021-2026)
  137. 6.23.4 Boehringer Ingelheim Pulmonary Drugs Product Portfolio
  138. 6.23.5 Boehringer Ingelheim Recent Developments
  139. 6.24 Aurobindo Pharma Ltd.
  140. 6.24.1 Aurobindo Pharma Ltd. Company Information
  141. 6.24.2 Aurobindo Pharma Ltd. Business Overview
  142. 6.24.3 Aurobindo Pharma Ltd. Pulmonary Drugs Revenue, Global Share and Gross Margin (2021-2026)
  143. 6.24.4 Aurobindo Pharma Ltd. Pulmonary Drugs Product Portfolio
  144. 6.24.5 Aurobindo Pharma Ltd. Recent Developments
  145. 6.25 Alaxia SAS
  146. 6.25.1 Alaxia SAS Company Information
  147. 6.25.2 Alaxia SAS Business Overview
  148. 6.25.3 Alaxia SAS Pulmonary Drugs Revenue, Global Share and Gross Margin (2021-2026)
  149. 6.25.4 Alaxia SAS Pulmonary Drugs Product Portfolio
  150. 6.25.5 Alaxia SAS Recent Developments
  151. 6.26 Aerogen Pharma Ltd.
  152. 6.26.1 Aerogen Pharma Ltd. Company Information
  153. 6.26.2 Aerogen Pharma Ltd. Business Overview
  154. 6.26.3 Aerogen Pharma Ltd. Pulmonary Drugs Revenue, Global Share and Gross Margin (2021-2026)
  155. 6.26.4 Aerogen Pharma Ltd. Pulmonary Drugs Product Portfolio
  156. 6.26.5 Aerogen Pharma Ltd. Recent Developments
  157. 6.27 Abbott Laboratories
  158. 6.27.1 Abbott Laboratories Company Information
  159. 6.27.2 Abbott Laboratories Business Overview
  160. 6.27.3 Abbott Laboratories Pulmonary Drugs Revenue, Global Share and Gross Margin (2021-2026)
  161. 6.27.4 Abbott Laboratories Pulmonary Drugs Product Portfolio
  162. 6.27.5 Abbott Laboratories Recent Developments
7 North America
  1. 7.1 North America Pulmonary Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Pulmonary Drugs Market Size by Country (2021-2026)
  3. 7.3 North America Pulmonary Drugs Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Pulmonary Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Pulmonary Drugs Market Size by Country (2021-2026)
  3. 8.3 Europe Pulmonary Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Pulmonary Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Pulmonary Drugs Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Pulmonary Drugs Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Pulmonary Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Pulmonary Drugs Market Size by Country (2021-2026)
  3. 10.3 South America Pulmonary Drugs Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Pulmonary Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Pulmonary Drugs Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Pulmonary Drugs Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst